Introduction
Senator Bill Cassidy of Louisiana, who chairs the Senate Health Committee, says he is still weighing his vote on President Trump's nominee to lead the Food and Drug Administration. With a committee vote set for November 18, Cassidy told CBS News that he has not yet decided whether to support Dr. Heidi Overton, citing unresolved concerns about her record and approach.
What Happened
During a Sunday appearance on "Face the Nation," Cassidy was asked directly whether Overton would secure approval. He replied that he could not predict the outcome, explaining that he has spent the week speaking with Overton, colleagues, and advisers. The senator previously characterized her role in reshaping the administration's vaccine policies as nearly disqualifying, though he has not ruled out supporting her.
Overton, a senior domestic policy adviser at the White House and a former policy official at a conservative think tank, defended the measles, mumps, and rubella vaccine during her September confirmation hearing, calling it safe and effective. She has also pushed back on claims from the president that the vaccine could be dangerous.
The stakes are heightened by the Senate's narrow partisan divide. Republicans hold only a one-vote advantage on the health panel, meaning a single Republican defection could defeat the nomination if Democrats vote unanimously against it. Cassidy also noted that he might leave the Senate in January without a permanent FDA commissioner in place, though he argued that an imperfect but confirmed leader is preferable to a string of temporary administrators.
Additional complications stem from broken assurances. Cassidy has linked Overton's nomination, along with that of National Science Foundation nominee James O'Neill, to promises made by Health and Human Services Secretary Robert F. Kennedy Jr. to secure Cassidy's own confirmation vote—promises that Cassidy says have not been kept. If confirmed, Overton would also oversee the FDA's safety review of mifepristone, the medication used in medication abortions. Trump nominated her roughly three months after Marty Makary stepped down as the agency's first commissioner under this administration.
Why This Matters
The outcome could shape the FDA's direction on vaccines, drug approvals, and reproductive health policy for years to come. A permanent commissioner would have more autonomy to set agency priorities than a series of acting leaders, who might be more directly influenced by the secretary of health and human services. Because Overton is openly opposed to abortion, her confirmation would place the future of mifepristone's regulatory status squarely in her hands.
The vote also serves as a test of Republican discipline during the lame-duck session. With Democrats poised to assume control of the Senate next year, the GOP is rushing to confirm as many Trump nominees as possible. Cassidy's hesitation shows that even committee chairs are not guaranteed votes, and it leaves the agency without confirmed leadership at a critical juncture.
Key Takeaways
- Senate Health Committee Chair Bill Cassidy remains undecided on Dr. Heidi Overton's FDA nomination.
- The committee is scheduled to vote on November 18.
- Republicans hold a one-vote majority on the panel, so one defection could sink the nomination.
- Cassidy has questioned Overton's role in vaccine policy but acknowledged the need for steady leadership at the FDA.
- Overton would oversee the FDA's review of mifepristone if confirmed.
- Trump nominated Overton after Marty Makary resigned as commissioner.
Conclusion
As the November 18 vote approaches, the future of the FDA remains uncertain. Cassidy's continued reservations highlight the pressure on Republican senators to balance loyalty to the administration with their own policy concerns. Whether Overton secures enough support to lead the agency—or whether the FDA enters 2027 without a confirmed commissioner—will depend on a handful of undecided votes in the coming days.

Discussion
Join the conversation
Thoughtful reactions, questions, and follow-up ideas help shape the next story.